Table 1.

Translational feasibility scores.

Tracer	Int	LE	Bind	Bright	Link	Yield	Total	Feasible?
Vedolizumab-800CW	100	92.0	71.5	71.2	95.4	84.4	514.5	Yes
Vedolizumab-680LT	100	89.3	63.8	78.8	100	84.6	516.5	Yes
Vedolizumab-ZW800	75.0	99.2	66.4	38.4	0.1	65.8	344.9	No
Infliximab-800CW	0.0	91.1	45.5	58.7	85.9	80.5	361.7	No
Infliximab-680LT	58.3	88.0	58.9	100	100	84.0	480.2	Potentially
Infliximab-ZW800	50.0	97.6	100	36.4	0.1	63.3	347.4	No
Adalimumab-800CW	100	86.6	88.5	69.2	90.9	67.3	502.5	Yes
Adalimumab-680LT	100	82.8	77.9	70.7	100	68.8	500.2	Yes
Adalimumab-ZW800	83.3	98.6	100	26.5	0.1	62.3	370.8	No
Ustekinumab-800CW	100	88.7	100	72.9	82.0	64.7	508.3	Yes
Ustekinumab-680LT	100	87.5	59.1	81.5	100	66.7	494.8	Potentially
Ustekinumab-ZW800	66.7	94.2	100	39.4	0.1	47.0	347.3	No

Each feasibility score calculated from 0–100. A score ≥ 500 is considered to correspond to a feasible candidate. Potentially feasible candidates don’t meet the set criteria, but may be optimized in specific areas to become feasible. Int: Antibody Integrity; LE: label efficiency; Bind: Target binding affinity; Bright: Fluorescent brightness; Link: Link stability.